Skip to main content
. 2020 Oct 22;2(11):2077–2085. doi: 10.1007/s42399-020-00602-8

Table 3.

Mucocutaneous findings in PIMS-TS

Study Findings n/N (%)
Toubiana et al. [2] Rash 16/21 (76)
Bilateral bulbar conjunctival injection 17/21 (81)
Lips and oral cavity changes 16/21 (76)
Whittaker et al. [3] Erythematous rash 30/58 (52)
Conjunctivitis 26/58 (45)
Mucus membrane changes and red cracked lips 17/58 (29)
Swollen hands and feet 9/58 (16)
Cabrero-Hernandez et al. [8] Maculopapular rash in genital 1/5 (20)
Maculopapular rash in trunk and extremities 1/5 (20)
Riphagen et al. [10] Conjunctivitis 5/8 (63)
Rash 4/8 (50)
Kaushik et al. [11] Mucocutaneous involvement 7/33 (21)
Conjunctivitis 12/33 (36)
Rash 14/33 (42)
Davies et al. [12] Conjunctivitis 23/78 (29)
Rash 35/78 (45)
Ng et al. [14] Conjunctivitis 3/3 (100)
Maculopapular rash 1/3 (33)
Urticarial rash 1/3 (33)
Cracked lips 1/3 (33)
Pouletty et al. [17] Skin rash 13/16 (81)
Hands/feet erythema 11/16 (68)
Conjunctivitis 15/16 (94)
Dry cracked lips 14/16 (87)
Grimaud et al. [18] Skin rash 10/20 (50)
Conjunctivitis 6/20 (30)
Cheilitis 5/20 (25)
Cheung et al. [20] Rash 12/17 (71)
Conjunctivitis 11/17 (65)
Lip redness/swelling 9/17 (53)